Aspirin with chemotherapy to improve ovarian tumor immune features
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This early-phase study tests whether adding aspirin to standard neoadjuvant chemotherapy can change immune (anti-tumor) features inside ovarian, fallopian tube, or peritoneal tumors. It may help doctors better understand which patients respond and how aspirin could make treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and you can read and understand the study language (English/Spanish or English/French).
- Your cancer is confirmed (or strongly suspected) to be epithelial ovarian, fallopian tube, or peritoneal cancer, and it is grade 2 or 3 (including “high”).
- You have not had treatment for this cancer yet, and you plan chemotherapy first (about 3 to 5 cycles) followed by interval debulking surgery.
- Your CT scan shows measurable disease within 12 weeks, and your overall functioning score is 0–2 (active but may need some help).
- You can provide a tumor tissue sample (biopsy) and you are willing to take aspirin pills as instructed and attend all visits and tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a statin (a common cholesterol-lowering drug) to standard chemotherapy can improve outcomes for people with ovarian cancer. It's for women who are about to receive chemotherapy as part of their treatment plan.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this treatment shrinks the cancer more and makes surgery more effective.
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests adding propranolol (a heart medication) to standard chemotherapy before surgery for advanced high-grade serous ovarian cancer. The goal is to see if this combination helps shrink tumors more effectively.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.